Category: receptor_pharmacology
Explains the gentle pins-and-needles tingling in fingers, toes, and sometimes lips that lands within days of starting topiramate, acetazolamide, or zonisamide — the most common reason users describe these medications as 'feeling weird.' All three are carbonic anhydrase (CA) inhibitors with varying isoform selectivity. CA catalyzes CO2 + H2O ↔ H+ + HCO3⁻ across many tissues — Maren 1967 is the foundational pharmacology review; Supuran 2008 catalogs the 15+ human isoforms. Topiramate inhibits CA II, IV, V, VI, and VII (Dodgson 2000); acetazolamide is a broad CA II/IV inhibitor; both produce a mild systemic metabolic acidosis through impaired renal HCO3⁻ reabsorption in the proximal tubule. The paresthesia is the class-typical adverse effect — incidence reported at 30-50% for topiramate, dose-dependent (Pearl 2023 narrative review). Mechanism for peripheral paresthesia is incompletely worked out but two contributors are recognized: (1) the systemic mild acidosis lowers ionized calcium availability at neuromuscular junctions and at peripheral sensory nerve endings, producing the same tingling-around-extremities pattern seen in hyperventilation tetany; (2) direct CA inhibition in peripheral nerve myelin and Schwann cells (CA II and IV are expressed there) raises local pH gradient sensitivity and may directly affect axonal excitability. The paresthesia is benign, tends to attenuate over weeks (partial tolerance), and is dose-dependent — most users tolerate it. Worth noting: the same drugs also produce a 'soda tastes weird' phenomenon (CA VI in saliva — carbonation-sensing impaired) and the 'topamax brain fog' phenomenology that is distinct from paresthesia and likely AMPA/kainate-related.